ArriVent BioPharma, Inc. AVBP Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s other commercial liabilities?
- ArriVent BioPharma, Inc. (AVBP) reported other commercial liabilities of $16.17M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s other commercial liabilities changed year-over-year?
- ArriVent BioPharma, Inc.'s other commercial liabilities increased by 91.3% year-over-year, from $8.45M to $16.17M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s other commercial liabilities?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s other commercial liabilities has grown at a 69.6% compound annual growth rate (CAGR), from $6.95M to $20M.